Supply High Purity 99% Clobetasol CAS 25122-41-2 Clobetasol Propionate

• Powder: Yes
• Customized: Customized
• Certification: GMP, ISO 9001, USP, BP
• Suitable for: Elderly, Adult
• State: Powder
• Purity: >98%
• Model NO.: TGY201905260702
• Appearance: White Powder
• Molecular Formula: C25h32clfo5
• Einecs No.: 246-634-3
• Certificate: ISO 9001, USP
• Shelf Life: 24 Months
• Storage: Cool Dry Area
• Grade: Pharmaceutical Grade
• CAS No.: 25122-41-2
• Sample: Avaliable
• Service: OEM
• MOQ: 20g
• Assay: 98%Min, 99% HPLC
• Test Method: USP;GMP
• Coa: Avaliable
• Keyword: Clobetasol Propionate
• Transport Package: Boil Bag
• Specification: HPLC 99%
• Trademark: TGY
• Origin: Xi′an, Shaanxi, China (Mainland)
• HS Code: 29329990
• Production Capacity: 3000kg/Month

Product Description

ITEMS		SPECIFICATION	RESULTS
BP2010 /EP6	Appearance	crystalline powder	Conforms
	Melting point	About 205°C	206.4°C~206.7°C
	Identification	Meet the requirements	Conforms
	Appearance of solution	Clear, not more intense than Y7	Conforms
	PH	2.4~3.0	2.60
	Loss on drying	≤0.5%	0.04%
	Sulphated ash	≤0.1%	0.01%
	Heavy metals	≤20 ppm	<20 ppm
	Related substances	≤0.25%	Conforms
	Assay	99.0%~101.0%	99.8%
USP32	Identification	Meet the requirements	Conforms
	Loss on drying	≤0.5%	0.04%
	Residue on ignition	≤0.1%	0.01%
	Heavy metals	≤0.003%	<0.003%
	Residue solvent - Ethanol	≤0.5%	<0.04%
	Chloride	16.9%~17.6%	17.1%
	Assay	98.0%~102.0%	100.0%
Conclusion: The product complies with BP2010/USP32/EP6 standard

Adrenocorticotropic hormone drugs, anti-inflammatory, anti-allergic, and anti-drug more effective than predn, and promoting the removal of potassium sodium retention is very light, intramuscular or intravenous pituitary-adrenal strong inhibition:

1. Anti-inflammatory effects: The product can reduce and prevent tissue response to inflammation, thereby reducing inflammation performance. Hormone suppression of inflammatory cells, including leukocytes and macrophages accumulation in sites of inflammation and inhibition of phagocytosis, lysosomal enzyme release, and synthesis, and release of inflammatory chemical mediators. Can reduce and prevent tissue response to inflammation, thereby reducing inflammation performance. 

2. Immunosuppressive effect: preventing or inhibiting cell-mediated immune response, delayed hypersensitivity reactions, reducing T lymphocytes, monocytes, eosinophils, reducing immunoglobulin binding to cell surface receptors, and inhibition of the synthesis and release of interleukin, thus reducing the T lymphocyte transformation of lymphoblastoid cells, and reduce the extension of the primary immune response. Can reduce immune complexes through the basement membrane, and can reduce the concentration of ingredients complement and immunoglobulins.